Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 149 of 6351
-
A simple urine test could revolutionize bladder cancer detection
Diagnosis Recruiting nowThis is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
Sponsor: Convergent Genomics, Inc. • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
Could early kangaroo care save more tiny newborns?
Disease control CompletedWe will conduct an individually randomised, controlled, superiority trial with two parallel groups; an intervention arm allocated to receive KMC and a control arm receiving 'standard' care. The primary aim is to examine the impact of KMC initiated before stabilisation on mortalit…
Sponsor: London School of Hygiene and Tropical Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Blood test could revolutionize colon cancer screening
Diagnosis OngoingThe ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 …
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Promising combo aims to stall aggressive breast cancer
Disease control OngoingThis study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into ot…
Phase 3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Tiny brain implant could give blind people a 'Limited sense of Sight'
Disease control Recruiting nowThe objective of this study is to evaluate the usefulness of a cortical visual prosthesis based on intracortical microelectrodes to provide a limited but useful sense of vision to profoundly blind. This pilot study will provide important information on safety and efficacy for the…
Sponsor: Universidad Miguel Hernandez de Elche • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a targeted botox shot quiet the Brain's pain center for chronic migraine?
Symptom relief CompletedThis is a clinical trial to assess the efficacy of botox treatment of the sphenopalatine ganglion as an add-on treatment in drug resistant migraine. An injection targeting the ganglion is made possible by an image-guided device developed specifically for this purpose (MultiGuide)…
Phase 3 • Sponsor: St. Olavs Hospital • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New combo therapy shows promise in battle against advanced liver cancer
Disease control CompletedThe main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Spinal shock: new combo may get paralyzed patients stepping overground
Disease control OngoingThe main goal of the project is to develop multiple noninvasive neuromodulatory strategies to facilitate full weight bearing stepping overground in people with paralysis. We will determine the effectiveness of combining noninvasive spinal cord stimulation and the administration o…
Early phase 1 • Sponsor: University of Louisville • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a modified herpes virus outsmart brain cancer?
Disease control CompletedThe purpose of this project is to obtain safety information in small groups of individuals, scheduled to receive escalating doses of C134, a cancer killing virus (HSV-1) that has been genetically engineered to safely replicate and kill glioma tumor cells. Safety will be assessed …
Phase 1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Once-a-Month shot tame MS relapses?
Disease control CompletedA multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, …
Phase 3 • Sponsor: Mapi Pharma Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a vaccine stop shingles from coming back? new study targets adults 50+
Vaccine CompletedThe purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 08:01 UTC
-
Brain gene therapy aims to silence Huntington's disease
Disease control OngoingThis is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase 1/2, multicenter, first-in-human (FIH) study. The first three cohorts of the study have completed enrollment, including t…
Phase 1/2 • Sponsor: UniQure Biopharma B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug patisiran aims to help hearts stiffened by rare protein disease
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
Phase 3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New combo therapy aims to beat back advanced hodgkin lymphoma
Disease control OngoingThis phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can three drugs together shrink Hard-to-Treat breast tumors?
Disease control OngoingThis study evaluates the efficacy of the combination of olaparib, durvalumab, and fulvestrant for the treatment of patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with BRCA gene alterations or alterations of genes involved in homologous reco…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent)…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a brain pacemaker tame Treatment-Resistant depression?
Disease control Recruiting nowThe goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 speci…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Experimental gene therapy offers hope for fatal nerve disease
Disease control Recruiting nowBackground: GM1 gangliosidosis is a disorder that destroys nerve cells. It is fatal. There is no treatment. People with GM1 are deficient in a certain enzyme. A gene therapy may help the body make this enzyme. This could improve GM1 symptoms. Objective: To test if a gene thera…
Phase 1/2 • Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New combo therapy aims to keep multiple myeloma in check longer
Disease control OngoingPatients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomi…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 17:23 UTC
-
New hope for progressive MS: ocrelizumab trial targets disability
Disease control OngoingThis study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study will consist of the following phases: screening, d…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC